Summit Therapeutics (SMMT) Assets Average (2020 - 2026)

Summit Therapeutics (SMMT) has 7 years of Assets Average data on file, last reported at $700.0 million in Q2 2026.

• Quarterly Assets Average rose 97.79% year-over-year to $700.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $700.0 million (up 97.79% YoY) and the FY2025 annual result came in at $593.4 million, up 85.86% from the prior year.
• Assets Average steadied at $700.0 million in Q2 2026, from $699.5 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $700.0 million in Q2 2026 to a low of $106.1 million in Q2 2022.
• A 5-year average of $344.7 million and a median of $323.4 million in 2025 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2023 — Assets Average surged 299.86% — and 2024, when it tumbled 58.68%.
• Tracing SMMT's Assets Average over 5 years: stood at $409.7 million in 2022, then plunged by 48.58% to $210.7 million in 2023, then jumped by 122.68% to $469.2 million in 2024, then advanced by 7.94% to $506.5 million in 2025, then soared by 38.22% to $700.0 million in 2026.
• The last three Assets Average figures came in at $700.0 million (Q2 2026), $699.5 million (Q1 2026), and $506.5 million (Q4 2025), per Business Quant data.